"The broad biotech group needs to see rationalization after an unprecedented period of capital raising in 2020 and 2021 as too many companies were funded and many at very early stages of development," says Marshall Gordon. He believes that large cap companies in the sector are flush with cash and face significant patent expirations. Next, Tom White discusses an example trade on iShares Biotechnology ETF (IBB) with a bullish direction.
23 Mar 2022
The Watch List
28 Mar 2022
Trading 360
11 Apr 2022
Morning Trade Live
18 Mar 2022
Market On Close
11 Apr 2022
Morning Trade Live
28 Mar 2022
Trading 360
09 Mar 2022